Expression of Fyn, a non-receptor tyrosine kinase in prefrontal cortex from patients with schizophrenia and its correlation with clinical onset

Molecular Brain Research

Volumn 112, Issue 1-2, 2003, Pages 90-94

  Ohnuma, Tohru ^a,b,d   Kato, Hidemasa ^b   Arai, Heii ^a   McKenna, Peter J ^c   Emson, Piers C ^b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BABRAHAM INSTITUTE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Juntendo University Hospital   (Japan)

Author keywords

Immunoreactivity; mRNA; Non receptor type protein tyrosine kinase; Onset of disease; Prefrontal cortex; Schizophrenia

Indexed keywords

MESSENGER RNA; PROTEIN; PROTEIN KINASE FYN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

AGED; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; ONSET AGE; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 0037430917     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(03)00051-2     Document Type: Article

References (24)

1. Ali D.W., Salter M.W. NMDA receptor regulation by Src kinase signalling in excitatory synaptic transmission and plasticity. Curr. Opin. Neurobiol. 11:2001;336-342.
2. Benes F.M., Majocha R., Bird E.D., Marotta C.A. Increased vertical axon numbers in cingulate cortex of schizophrenics. Arch. Gen. Psychiatry. 44:1987;1017-1021.
3. Benes F.M., Sorensen I., Vincent S.L., Bird E.D., Sathi M. Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain. Cereb. Cortex. 2:1992;503-512.
4. DeLisi L.E., Hoff A.L., Schwartz J.E., Shields G.W., Halthore S.N., Gupta S.M., Henn F.A., Anand A.K. Brain morphology in first-episode schizophrenic-like psychotic patients: a quantitative magnetic resonance imaging study. Biol. Psychiatry. 29:1991;159-175.
5. Grant S.G., O'Dell T.J., Karl K.A., Stein P.L., Soriano P., Kandel E.R. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science. 258:1992;1903-1910.
6. Hakak Y., Walker J.R., Li C., Wong W.H., Davis K.L., Buxbaum J.D., Haroutunian V., Fienberg A.A. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc. Natl. Acad. Sci. USA. 98:2001;4746-4751.
7. Harrison P.J. Schizophrenia: a disorder of neurodevelopment? Curr. Opin. Neurobiol. 7:1997;285-289.
8. Javitt D.C. Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J. Clin. Psychiatry. 9:1987;12-35.
9. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
10. Kerwin R., Patel S., Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post-mortem. Neuroscience. 39:1990;25-32.
11. Kiryu S., Yao G.L., Morita N., Kato H., Kiyama H. Nerve injury enhances rat neuronal glutamate transporter expression: identification by differential display PCR. J. Neurosci. 15:1995;7872-7878.
12. Lafargue T., Brasic J. Neurodevelopmental hypothesis of schizophrenia: a central sensory disturbance. Med. Hypotheses. 55:2000;314-318.
13. Lewis D.A. Development of the prefrontal cortex during adolescence: insights into vulnerable neural circuits in schizophrenia. Neuropsychopharmacology. 16:1997;385-398.
14. Miyakawa T., Yagi T., Watanabe S., Niki H. Increased fearfulness of Fyn tyrosine kinase deficient mice. Brain Res. Mol. Brain Res. 27:1994;179-182.
15. Ohnuma T., Augood S.J., Arai H., McKenna P.J., Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res. Mol. Brain Res. 56:1998;207-217.
16. Ohnuma T., Augood S.J., Arai H., McKenna P.J., Emson P.C. Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABAA receptor a-1 subunit mRNA and human GABA transporter 1 (hGAT-1) mRNA expression. Neuroscience. 93:1999;441-448.
17. Ohnuma T., Kato H., Arai H., Faull R.L., McKenna P.J., Emson P.C. Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. Neuroreport. 11:2000;3133-3137.
18. Ohnuma T., Kimura M., Takahashi T., Iwamoto N., Arai H. A magnetic resonance imaging study in first-episode disorganized-type patients with schizophrenia. Psychiatry Clin. Neurosci. 51:1997;9-15.
19. Roberts R.C., Conley R., Kung L., Peretti F.J., Chute D.J. Reduced striatal spine size in schizophrenia: a postmortem ultrastructural study. Neuroreport. 7:1996;1214-1218.
20. Saito R., Fujita N., Nagata S. Overexpression of Fyn tyrosine kinase causes abnormal development of primary sensory neurons in Xenopus laevis embryos. Dev. Growth Differ. 43:2001;229-238.
21. Senitz D., Winkelmann E. Neuronal structure abnormality in the orbito-frontal cortex of schizophrenics. J. Hirnforsch. 32:1991;149-158.
22. Shapiro R.M. Regional neuropathology in schizophrenia: where are we? Where are we going? Schizophr. Res. 10:1993;187-239.
23. Sperber B.R., Boyle-Walsh E.A., Engleka M.J., Gadue P., Peterson A.C., Stein P.L., Scherer S.S., McMorris F.A. A unique role for Fyn in CNS myelination. J. Neurosci. 21:2001;2039-2047.
24. Umemori H., Wanaka A., Kato H., Takeuchi M., Tohyama M., Yamamoto T. Specific expressions of Fyn and Lyn, lymphocyte antigen receptor-associated tyrosine kinases, in the central nervous system. Brain Res. Mol. Brain Res. 16:1992;303-310.